Development of NET theranosptic agents based on novel 64Cu-labeled somatostatin derivatives

Research Project

Project/Area Number	15K19824
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Radiation science
Research Institution	Suzuka University of Medical Science
Principal Investigator	Fujisawa Yutaka 鈴鹿医療科学大学, 薬学部, 助手 (30511993)
Project Period (FY)	2015-04-01 – 2017-03-31
Project Status	Completed (Fiscal Year 2016)
Budget Amount *help	¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000) Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000) Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Keywords	神経内分泌腫瘍 / ソマトスタチン誘導体 / 64Cuキレーター / ATSM誘導体 / 診断／治療薬開発 / 診断／治療用薬剤開発
Outline of Final Research Achievements	Radiolabeled somatostatin (SST) analogues are useful for diagnosis and therapy of neuroendcrine tumor (NET). The aim of this study is to develop a novel theranostic agent which enables to perform both diagnosis and therapy of NET, we designed and synthesized novel Cu-64-labeled SST analogues. Administration of them in the model mice implanted AR42J cells before acquiring time-dependent PET images contributed to obtain clear tumor images. In addition, higher accumulation of Cu-64 over a prolonged period to AR42J tumor were observed in mice administrated a novel radiolabeled SST than in mice administrated a reference SST analogue. These results suggest the usability of Cu-64-labeled SST analogue as a novel agent for NET diagnosis.